Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia
cell population that gives rise to relapse of the disease. The detection of MRD is critical for …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

New techniques are on the horizon for the detection of small leukemic clones in both, acute
leukemias and myeloproliferative disorders. A promising approach is based on digital …

Real-time quantitative PCR (qPCR) is routinely used to detect minimal residual disease in
chronic myeloid leukemia patients. The absolute quantification with droplet digital PCR …

Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic
leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise …

Bone marrow (BM) chimeric mice are a valuable tool in the field of immunology, with the
genetic manipulation of donor cells widely used to study gene function under physiological …

BACKGROUND The analytically sensitive detection of KIT D816V in blood and bone marrow
is important for diagnosing systemic mastocytosis (SM). Additionally, precise quantification …

Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in
such a way that patients with adequate access to these agents, who are properly managed …

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …

Standardized monitoring of BCR:: ABL1 mRNA levels is essential for the management of
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …